tag:blogger.com,1999:blog-33960805.post3652976007873688032..comments2023-10-30T02:03:47.513-07:00Comments on Clinical Psychology and Psychiatry: A Closer Look: Seroquel for Everything and Academic SpokespeopleCL Psychhttp://www.blogger.com/profile/13990549972520745769noreply@blogger.comBlogger3125tag:blogger.com,1999:blog-33960805.post-75645824015434152072007-12-07T20:36:00.000-08:002007-12-07T20:36:00.000-08:00Anon, Thanks for the additional info.Jack,Thanks f...Anon, <BR/><BR/>Thanks for the additional info.<BR/><BR/>Jack,<BR/><BR/>Thanks for the feedback and for linking it on your site. It is indeed very disheartening...CL Psychhttps://www.blogger.com/profile/13990549972520745769noreply@blogger.comtag:blogger.com,1999:blog-33960805.post-58992033318072883972007-12-07T07:19:00.000-08:002007-12-07T07:19:00.000-08:00Great job.This sickens me.....JackGreat job.<BR/><BR/>This sickens me.....<BR/><BR/>JackAnonymousnoreply@blogger.comtag:blogger.com,1999:blog-33960805.post-52217319842782352962007-12-06T08:27:00.000-08:002007-12-06T08:27:00.000-08:00Way back when, Stuart Montgomery, then of St. Mary...Way back when, Stuart Montgomery, then of St. Mary’s hospital medical school in London was co-author of a paper bigging up Paxil.<BR/><BR/>See below:<BR/><BR/>Dr. David Dunner of the University of Washington’s Department of Psychiatry admitted he “ghostwrote” an article that appeared in the March 1995 issue of the journal European Neuropsychopharmacology (EN) on behalf of pharmaceutical manufacturer SmithKline-Beecham (which has since merged with GlaxoWellome to become Glaxo-Smith-Kline, or GSK). Dunner had purportedly analyzed the data of clinical studies involving GSK’s antidepressant and anti-anxiety drug Paxil and concluded that it is less likely to lead to suicidal thoughts than the older antidepressant imipramine or a placebo(sugar pill).<BR/><BR/>Dunner never looked at any of the data but he was still listed as an “author” of the article.<BR/><BR/>Meanwhile, Dr. David Healy of the University of Wales Department of Psychological Medicine presented a different analysis of this same data during the Paxil trial [of 2001]. The family of Wyoming resident Donald Schell, 60, sued GSK in federal court after Schell shot his wife, daughter, granddaughter and then himself to death in 1998 after two days on Paxil. Healy testified on behalf of the plaintiffs. He argued GSK’s internal records demonstrated that there is a substantially increased suicide risk for patients put on Paxil. The jury agreed with the plaintiff’s position that Paxil was primarily responsible for Schell’s actions and awarded them $6.4 million in June of [2001]. The judge in the case rejected GSK’s challenge of Healy’s testimony and sent them packing to a federal appeals court in Denver in August.<BR/><BR/>A suicide warning has since been put on the label for the drug, not here in the United States, but in Britain, where it is known as Seroxat.<BR/><BR/>Dunner’s record also includes eight statements of significant financial interest. The most significant with regard to the Paxil clinical trial data is a disclosure he made in 1998. The disclosure was made regarding an application for a clinical trial dealing with Paxil in which Dunner would serve as an investigator at his Center for Anxiety and Depression. His Confidential Statement to the Vice Provost for Research states, “My involvement with SmithKlineBeecham (the pre-Glaxo merger owner of Paxil) involves being a member of the international advisory board related to paroxetine (Paxil).” In other words, Dunner’s name appeared in the EN article not as an independent scientist but most likely as a part-time employee of the manufacturer of Paxil. This conflict of interest is not mentioned in the EN article.Anonymousnoreply@blogger.com